HKI-272

neratinib · Puma Biotechnology

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for HKI-272, covering 2012-05-14 to 2018-02-19. Get the full timeline:

Most recent: Clinical Trial Update: A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors [Phase 1]

See pricing